
Ernexa Therapeutics Inc. (ERNA) Stock Ticker
ERNA right now
Market factors today
Unlock the full ERNA picture
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
ERNA stock facts
| Ticker symbol | ERNA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.1M |
| CEO | Sanjeev Luther |
| Employees | 5 |
| Headquarters | Cambridge, MA, US |
| IPO date | 1991-08-29 |
| Website | www.ernexatx.com |
What you can see for ERNA on Tickr
Live ERNA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ERNA report.
Rankings
FAQ
What is the ticker symbol for Ernexa Therapeutics Inc.?
The ticker symbol for Ernexa Therapeutics Inc. is ERNA, listed on the NASDAQ Global Market.
What is ERNA?
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory…